Compare CPSH & GLTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPSH | GLTO |
|---|---|---|
| Founded | 1984 | 2011 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.6M | 54.5M |
| IPO Year | 1995 | 2020 |
| Metric | CPSH | GLTO |
|---|---|---|
| Price | $4.46 | $30.02 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $6.00 | ★ $43.67 |
| AVG Volume (30 Days) | ★ 362.6K | 298.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.03 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $55.87 | N/A |
| Revenue Next Year | $19.98 | N/A |
| P/E Ratio | $149.00 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.40 | $2.01 |
| 52 Week High | $6.85 | $38.33 |
| Indicator | CPSH | GLTO |
|---|---|---|
| Relative Strength Index (RSI) | 46.06 | 56.38 |
| Support Level | $4.36 | $3.22 |
| Resistance Level | $4.89 | $32.63 |
| Average True Range (ATR) | 0.37 | 2.93 |
| MACD | -0.10 | 0.42 |
| Stochastic Oscillator | 26.70 | 71.92 |
CPS Technologies Corp provides material solutions to the transportation, automotive, energy, computing/Internet, telecommunications, aerospace, defense, and oil and gas end markets. Its primary material solution is metal matrix composites (MMCs), which are a class of materials consisting of a combination of metal and ceramic. The company designs, manufactures and sells custom MMC components, which manages the performance and reliability of systems in the end markets. It also provides baseplates and housings used in radar, satellite and avionics applications. The company provides lids and heat spreaders used with integrated circuits in Internet switches and routers.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of cancer and liver diseases. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.